Description
Irbesartan is an angiotensin II type 1 (AT1) receptor inhibitor that also activates PPARγ receptors; it exhibits antihypertensive, cardioprotective, and anti-hyperlipidemic activities. In angiotensin-converting enzyme 2 (ACE2)-deficient mice, irbesartan decreases TGF-β1, atrial natriuretic factor, collagen, and phospho-ERK1/2 expression and increases PPARγ expression, reversing cardiac hypertrophy and myocardial fibrosis. In animal models of angiotensin II (ATII)-mediated abdominal aortic aneurysm, irbesartan prevents macrophage infiltration, pro-inflammatory cytokine release, smooth muscle attenuation, and medial elastolysis, and also limits aneurysm enlargement. In obese hypertensive rats, this compound decreases plasma levels of free fatty acids, triglycerides, and insulin; it also upregulates expression of hepatic PPARα. In high fat diet rats, irbesartan decreases body weight and adipose tissue weight and improves glucose metabolism and vascular function.
References
Zhang ZZ, Shang QH, Jin HY, et al. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. J Transl Med. 2013 Sep 25;11(1):229. PMID: 24067190.
Iida Y, Xu B, Schultz GM, et al. Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One. 2012;7(12):e49642. PMID: 23226500
Rong X, Li Y, Ebihara K, et al. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. Br J Pharmacol. 2010 Aug;160(7):1796-807. PMID: 20649581
de las Heras N, Martín-Fernández B, Miana M, et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens Suppl. 2009 Aug;27(6):S37-41. PMID: 19633450.
Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol. 1999 Nov 18;84(10A):3S-8S. PMID: 10588088.
